Valuation : Recordati

Market Cap 10.78B 12.51B 10.11B 9.23B 17.39B 1,196B 17.44B 120B 46.8B 604B 46.98B 45.96B 2,002B P/E 2026 *
21.2x
P/E 2027 * 17.5x
Enterprise Value 12.53B 14.54B 11.75B 10.73B 20.21B 1,390B 20.27B 139B 54.4B 702B 54.61B 53.42B 2,327B EV / Sales 2026 *
4.5x
EV / Sales 2027 * 4.06x
Free-Float
50.46%
Yield 2026 *
2.9%
Yield 2027 * 3.22%
1 day-3.33%
3 months-3.33%
6 months+1.84%
Current year-11.37%
Current year 55.88
Extreme 55.88
60
1 year 55.88
Extreme 55.88
60
3 years 49
Extreme 49
65.44
5 years 36
Extreme 36
65.44
10 years 31.7
Extreme 31.7
65.44
Manager TitleAgeSince
Chief Executive Officer 64 01/12/2021
Director of Finance/CFO 56 01/01/2026
Chief Tech/Sci/R&D Officer 56 01/10/2023
Director TitleAgeSince
Chairman 54 01/12/2021
Chairman 57 12/06/2018
Director/Board Member 53 12/06/2018
Change 5-day change 1-year change 3-year change Capi.($)
-3.33%-.--% - - 12.56B
-0.60%-6.88%+59.71%+111.05% 1,048B
+0.05%-1.65%+51.49%+61.78% 640B
-0.59%-3.14%+23.44%+74.08% 456B
-1.46%-4.50%+37.43%+38.41% 362B
-0.72%-2.89%+21.86%+36.79% 295B
-1.19%-2.21%+1.35%+10.79% 255B
-1.09%-1.60%+51.36%+68.51% 236B
+0.08%-1.78%-17.64%-54.29% 204B
-2.32%-0.38%+29.32%+88.95% 185B
Average -1.07%-0.72%+28.70%+48.45% 409.07B
Weighted average by Cap. -0.66%-1.92%+38.18%+64.87%

Financials

2026 *2027 *
Net sales 2.79B 3.23B 2.61B 2.39B 4.49B 309B 4.51B 31.01B 12.1B 156B 12.15B 11.88B 517B 3.01B 3.49B 2.82B 2.57B 4.85B 334B 4.86B 33.45B 13.05B 168B 13.1B 12.82B 558B
Net income 566M 657M 530M 484M 912M 62.75B 915M 6.29B 2.46B 31.67B 2.46B 2.41B 105B 672M 780M 630M 576M 1.08B 74.58B 1.09B 7.48B 2.92B 37.65B 2.93B 2.87B 125B
Net Debt 1.75B 2.03B 1.64B 1.5B 2.82B 194B 2.83B 19.46B 7.59B 97.97B 7.62B 7.46B 325B 1.42B 1.65B 1.33B 1.22B 2.29B 158B 2.3B 15.81B 6.17B 79.57B 6.19B 6.06B 264B
Logo Recordati
Recordati S.p.A. specializes in the research, development, production and marketing of pharmaceutical products. Net sales break down by family of products as follows: - pharmaceutical and OTC products (58.7%): for the treatment of viral infections, cardiovascular, dermatological, gynecological diseases, etc.; - medicines for rare diseases (41.3%). Net sales are distributed geographically as follows: Italy (12.6%), Europe (53.7%), America (23.1%), Asia and Oceania (7.8%) and Africa (2.8%).
Employees
4,654
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
52.65EUR
Average target price
59.26EUR
Spread / Average Target
+12.55%

Quarterly revenue - Rate of surprise